Log in

NASDAQ:SYBX - Synlogic Stock Price, Forecast & News

$1.84
-0.01 (-0.54 %)
(As of 03/31/2020 06:59 AM ET)
Today's Range
$1.75
Now: $1.84
$1.89
50-Day Range
$1.39
MA: $2.14
$2.82
52-Week Range
$1.35
Now: $1.84
$10.01
Volume138,400 shs
Average Volume373,351 shs
Market Capitalization$59.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Read More
Synlogic logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.22 million
Book Value$4.86 per share

Profitability

Net Income$-51,370,000.00
Net Margins-2,310.98%

Miscellaneous

Employees74
Market Cap$59.34 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.


Synlogic (NASDAQ:SYBX) Frequently Asked Questions

How has Synlogic's stock been impacted by COVID-19 (Coronavirus)?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYBX stock has increased by 19.5% and is now trading at $1.84. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Synlogic?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Synlogic.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Synlogic.

How were Synlogic's earnings last quarter?

Synlogic Inc (NASDAQ:SYBX) issued its quarterly earnings results on Thursday, March, 12th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.07. The biotechnology company had revenue of $1.23 million for the quarter, compared to analysts' expectations of $0.63 million. Synlogic had a negative return on equity of 33.22% and a negative net margin of 2,310.98%. View Synlogic's earnings history.

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic's stock reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

7 Wall Street analysts have issued twelve-month price objectives for Synlogic's shares. Their forecasts range from $2.00 to $25.00. On average, they anticipate Synlogic's stock price to reach $14.17 in the next year. This suggests a possible upside of 669.9% from the stock's current price. View analysts' price targets for Synlogic.

Has Synlogic been receiving favorable news coverage?

News stories about SYBX stock have been trending very negative on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Synlogic earned a news impact score of -3.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutSynlogic.

Who are some of Synlogic's key competitors?

What other stocks do shareholders of Synlogic own?

Who are Synlogic's key executives?

Synlogic's management team includes the following people:
  • Dr. Peter Barrett, Exec. Chairman (Age 66)
  • Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)
  • Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO, Chief Medical Officer & Director (Age 43)
  • Prof. Timothy K. Lu, Co-Founder
  • Dr. James J. Collins, Co-Founder

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $1.84.

How big of a company is Synlogic?

Synlogic has a market capitalization of $59.34 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe. View additional information about Synlogic.

What is Synlogic's official website?

The official website for Synlogic is http://www.synlogictx.com/.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]


MarketBeat Community Rating for Synlogic (NASDAQ SYBX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  244 (Vote Underperform)
Total Votes:  531
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel